



Company Overview

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is a leading global pharmaceutical company that delivers high-quality, patient-centric healthcare solutions to millions of patients every day. Headquartered in Israel, Teva is the world's largest generic medicines producer, leveraging its portfolio of more than 1,000 molecules to produce a wide range of generic products in nearly every therapeutic area. In specialty medicines, Teva has a world-leading position in innovative treatments for disorders of the central nervous system, including pain, as well as a strong portfolio of respiratory products. Teva integrates its generics and specialty capabilities in its global research and development division to create new ways of addressing unmet patient needs by combining drug development capabilities with devices, services and technologies. Teva's net revenues in 2015 amounted to \$19.7 billion. For more information, visit www.tevapharm.com.


2015 Cash Flow and EBITDA (non GAAP¹)




2015 Stock Performance




Net Revenues (USD m)




Net Income (non GAAP¹) (USD m)



Earnings Per Share (non GAAP¹) (USD)



Dividends Per Share (USD)



(1) See non GAAP reconciliation in our report for the (4th Quarter 2015)

2015 Business Highlights



- Revenues of \$19.7 billion, an increase of 4% in local currency terms
- Record EPS 5.42 (Non-GAAP)
- Improved profitability: gross margin by 230bps to 62.2% and operating margin by 270bps to 31.4%
- Cash Flow from operations of 5.5 billion, up 8%; free cash flow of 4.9 billion up 15%

2015 Business Development

- March 30 - Teva reinforces leadership position in CNS with acquisition of Auspex
- July 27 - Teva announced an agreement to acquire Actavis's generic business; Creating a transformative generics and specialty pharma company well positioned to win in global Healthcare
- October 1 - Teva accelerates its emerging markets growth strategy with the acquisition of Rimsa
- November 30 - Teva and Takeda establish a unique partnership to meet the wide-ranging needs of patients in Japan


Revenues by Markets and Segments

FY - 2015



Profit** by Segment

FY - 2015



* Other activities include our OTC business with P&G, distribution services primarily in Israel and Hungary, and sales of medical devices

** Profit consists of gross profit, less S&M and R&D expenses related to the segment. Segment profitability does not include G&A expenses, amortization and certain other items.

Teva Specialty pipeline

Phase 1	Phase 2	Phase 3	Registration
TV-46139 (abuse deterrent) Pain	TV-45070 Topical Neuropathic pain	TEV-48125 (anti CGRP) Chronic and episodic migraine	Vantrela ER abuse deterrent Hydrocodone US Pain
TEV-90105 (abuse deterrent) Pain	Laquinimod Multiple sclerosis (progressive forms)	TV-46763 (abuse deterrent) Pain	TEV-90109 Opioid addiction
SD-809 (deutetrabenazine) Tourette syndrome	Laquinimod Huntington disease	Laquinimod Multiple sclerosis (relapsing remitting)	Copaxone® 40mg 3w ROW Multiple sclerosis
SD-1077 (deuldopa) Parkinson's Disease	Pridopidine Huntington disease	SD-809 (deutetrabenazine) Tardive dyskinesia	SD-809 (deutetrabenazine) Huntington Disease
SD-560 (deupirfenidone) Idiopathic pulmonary fibrosis	CEP-41750 (mesenchymal precursor cell) Acute myocardial infarction	Fluticasone Propionate MDPI Asthma	Reslizumab IV Asthma
Fluticasone Salmeterol (MDI) EU Asthma, COPD		Fluticasone Salmeterol MDPI Asthma	Fluticasone Salmeterol Spiromax EU Asthma, COPD
TEV-46017 (tidal inhaler) COPD		QVAR® (BAI) US Asthma	
TEV-48107 (tidal inhaler) COPD		Reslizumab SC Asthma	
TEV-90110 HIV		CEP-41750 (mesenchymal precursor cell) Chronic heart failure	
TEV-90111 HIV			
TEV-90112 HIV			
TEV-90113 HIV			

■ Migraine & Pain
■ Movement Disorders & Neurodegeneration
■ Respiratory
■ Other

Note: Pipeline is correct as of February 7th 2016. Phase 1 includes also projects designated for IND filing.